Attorneys at Ballard Spahr on Wednesday removed a lawsuit against CSL Behring LLC to District of Columbia District Court. The suit, over alleged gender-based employment discrimination, was filed by ...

Elizabeth McManus of Ballard Spahr has entered an appearance for CSL Behring LLC in a pending breach-of-contract lawsuit. The suit, seeking one-off cash based long term incentive payment, was filed ...

Following a complete response letter issued last October over CMC issues, CSL Behring LLC gained U.S. FDA approval June 16 of its humanized anti-factor XIIa monoclonal antibody, garadacimab (CSL-312), ...

Management reaffirmed guidance for fiscal 2025, expecting revenue growth of 5% to 7% and NPATA between AUD 3.2 billion to AUD ...

The U.S. FDA clearance June 16 of CSL Behring LLC’s humanized anti-factor XIIa monoclonal antibody garadacimab (CSL-312) to prevent hereditary angioedema (HAE) attacks juiced up the space in which – ...

CSL to axe up to 3,000 employees and spin off vaccine arm; shares tumble Australian biotech CSL, the country's fourth-largest company, said on Tuesday it would spin off its vaccine division and shed ...